|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash at bank | |||||||||||||
| Current assets: | |||||||||||||
| Cash at bank | |||||||||||||
| Prepayment | |||||||||||||
| Total current assets | |||||||||||||
| Cash and investments held in trust account | |||||||||||||
| TOTAL ASSETS | |||||||||||||
| Current liabilities: | |||||||||||||
| Accrued expenses | |||||||||||||
| Promissory note - related party | |||||||||||||
| Related Party | |||||||||||||
| Extension promissory note payable | |||||||||||||
| Amount due to a related party | |||||||||||||
| Total current liabilities | |||||||||||||
| Deferred underwriting compensation | |||||||||||||
| Deferred underwriting compensation | |||||||||||||
| TOTAL LIABILITIES | |||||||||||||
| Ordinary shares, 1,090,446 and 4,822,346 shares subject to possible redemption issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | |||||||||||||
| Shareholders’ Deficit: | |||||||||||||
| Ordinary shares, $0.0001 par value; 500,000,000 shares authorized; 4,416,075 shares issued and outstanding as of June 30, 2026 and December 31, 2025 (excluding 1,090,446 and 4,822,346 shares subject to possible redemption, respectively) | |||||||||||||
| Accumulated other comprehensive income | |||||||||||||
| Accumulated deficit | |||||||||||||
| Total Shareholders’ Deficit | |||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT | |||||||||||||
Loading...
